Tyrosine kinase inhibitor

DRUG CLASS:

Tyrosine kinase inhibitor

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive: A2 - Guideline Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive : A2	Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive: A2 - Guideline Tyrosine kinase inhibitor + vincristine + dexamethasone Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	Immunotherapy + Tyrosine kinase inhibitor Sensitive: A2 - Guideline Immunotherapy + Tyrosine kinase inhibitor Sensitive : A2	Immunotherapy + Tyrosine kinase inhibitor Sensitive: A2 - Guideline Immunotherapy + Tyrosine kinase inhibitor Sensitive : A2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: B - Late Trials Tyrosine kinase inhibitor Sensitive : B	Tyrosine kinase inhibitor Sensitive: B - Late Trials Tyrosine kinase inhibitor Sensitive : B
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	CLN-081 Sensitive: B - Late Trials CLN-081 Sensitive : B	CLN-081 Sensitive: B - Late Trials CLN-081 Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	befotertinib Sensitive: C2 – Inclusion Criteria befotertinib Sensitive : C2	befotertinib Sensitive: C2 – Inclusion Criteria befotertinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	rilertinib Sensitive: C2 – Inclusion Criteria rilertinib Sensitive : C2	rilertinib Sensitive: C2 – Inclusion Criteria rilertinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	BBT-176 Sensitive: C2 – Inclusion Criteria BBT-176 Sensitive : C2	BBT-176 Sensitive: C2 – Inclusion Criteria BBT-176 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	Tyrosine kinase inhibitor + capecitabine Sensitive: C2 – Inclusion Criteria Tyrosine kinase inhibitor + capecitabine Sensitive : C2	Tyrosine kinase inhibitor + capecitabine Sensitive: C2 – Inclusion Criteria Tyrosine kinase inhibitor + capecitabine Sensitive : C2
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ALK rearrangement	Lung Adenocarcinoma	ALK rearrangement	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ASXL1 mutation	Chronic Myeloid Leukemia	ASXL1 mutation	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR mutation + KRAS mutation	Non Small Cell Lung Cancer	EGFR mutation + KRAS mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
FGFR1 overexpression + HR positive	HER2 Negative Breast Cancer	FGFR1 overexpression + HR positive	HER2 Negative Breast Cancer	E 3810 Sensitive: C3 – Early Trials E 3810 Sensitive : C3	E 3810 Sensitive: C3 – Early Trials E 3810 Sensitive : C3
IFI27 underexpression	Lung Adenocarcinoma	IFI27 underexpression	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR overexpression	Lung Adenocarcinoma	EGFR overexpression	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ROS1 rearrangement	Lung Adenocarcinoma	ROS1 rearrangement	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma	EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR mutation + TP53 mutation	Lung Adenocarcinoma	EGFR mutation + TP53 mutation	Lung Adenocarcinoma	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
FGFR2-BICC1 fusion	Cholangiocarcinoma	FGFR2-BICC1 fusion	Cholangiocarcinoma	infigratinib + PD173074 Sensitive: C3 – Early Trials infigratinib + PD173074 Sensitive : C3	infigratinib + PD173074 Sensitive: C3 – Early Trials infigratinib + PD173074 Sensitive : C3

Tyrosine kinase inhibitor

Tyrosine kinase inhibitor

Associations(107)

Associations
(107)